Human liver stem cells improve liver injury in a model of fulminant liver failure
Maria Beatriz Herrera, Valentina Fonsato, Stefania Bruno, Cristina Grange, Nicholas Gilbo, Renato Romagnoli, Ciro Tetta, Giovanni Camussi – 24 July 2012 – Liver transplantation is currently the only effective therapy for fulminant liver failure, but its use is limited by the scarcity of organs for transplantation, high costs, and lifelong immunosuppression. Here we investigated whether human liver stem cells (HLSCs) protect from death in a lethal model of fulminant liver failure induced by intraperitoneal injection of D‐galactosamine and lipopolysaccharide in SCID mice.